Sign in

CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company

Olema Oncology, Inc.

Sign in to watch
Ticker
OLMA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
300409740
Phone
(415) 651-3316
Business address
365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
Former names
Olema Pharmaceuticals, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 17 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2021-05-18 Horn Kinney CHIEF BUSINESS OFFICER Option exercise +57,763 $2.06 $119K 59,553
2021-05-18 Horn Kinney CHIEF BUSINESS OFFICER Sale −49,142 $24.03 $1.2M 10,411
2021-05-18 Horn Kinney CHIEF BUSINESS OFFICER Sale −8,621 $24.81 $214K 1,790
2021-05-18 Horn Kinney CHIEF BUSINESS OFFICER Option exercise · Stock Option (Right to Buy) −57,763 194,297
2021-04-05 Larson Yi Director Grant or award · Stock Option (Right to Buy) +21,520 21,520
2021-04-05 Larson Yi Director Grant or award · Stock Option (Right to Buy) +3,773 3,773
2021-03-31 BVF PARTNERS L P/IL Director Other acquisition +99,556 99,556
2021-03-15 Horn Kinney Chief Business Officer Grant or award · Stock Option (Right to Buy) +40,000 40,000
2021-03-15 Bohen Sean President and CEO Grant or award · Stock Option (Right to Buy) +75,000 75,000
2020-11-23 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner Conversion +1,273,420 1,273,420
2020-11-23 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner Conversion +451,986 1,725,406
2020-11-23 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner Conversion · Series B Preferred Stock −1,273,420 0
2020-11-23 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner Conversion · Series C Preferred Stock −451,986 0
2020-11-23 Cormorant Asset Management, LP Former 10% Owner Conversion +2,845,544 2,845,544
2020-11-23 Cormorant Asset Management, LP Former 10% Owner Purchase +425,000 $19.00 $8.1M 3,270,544
2020-11-23 Cormorant Asset Management, LP Former 10% Owner Conversion · Series B Convertible Preferred Stock −2,122,367 0
2020-11-23 Cormorant Asset Management, LP Former 10% Owner Conversion · Series C Convertible Preferred Stock −723,177 0
2020-11-23 Graham G. Walmsley Director Conversion +1,400,761 1,400,761
2020-11-23 Graham G. Walmsley Director Conversion +1,183,114 1,183,114
2020-11-23 Graham G. Walmsley Director Purchase +1,160,000 $19.00 $22.0M 1,160,000

Page 19 of 21 · 402 trades